Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOKE plus oral semaglutide in early Alzheimer's disease
2020-004864-25Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Oral semaglutide with Placebo (2 arms). Primary endpoint: Change in Clinical Dementia Rating - Sum of Boxes. Started Feb 2021; status: active.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2020-004864-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004864-25.